Eisbach Bio corrects epigenetic errors in tumors

Spin-Off of the Biomedical Center

Eisbach Bio is an innovative start-up in biotechnology founded in 2019 as a spin-off of the Biomedical Center Munich. They are ­developing novel drugs that successfully target molecular vulnerabilities arising in cancer genomes. Thanks to a unique screening approach, Eisbach will establish cures for tumors that currently have no viable therapeutic option. In combination with existing drugs, the molecules will also make current therapies much more effective and greatly reduce their negative side-effects. Furthermore, by inhibiting genome evolution, the start-up will increase the number of patients that can benefit from cancer immunotherapy. Eisbach wants to beat cancer at its own game.